Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A novel therapeutic approach.

Margo A Denke1

  • 1University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390, USA. Margo.Denke@UTSouthwestern.edu

Journal of Managed Care Pharmacy : JMCP
|November 14, 2003
PubMed
Summary

New guidelines target low-density lipoprotein cholesterol (LDL-C) more aggressively. Ezetimibe, a novel cholesterol absorption inhibitor, offers a new treatment option for patients needing LDL-C reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changing Dietary Habits and Improving the Healthiness of Diets in the United States.

JAMA·2016
Same author

Comparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral density.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2007
Same author

Dietary fats, fatty acids, and their effects on lipoproteins.

Current atherosclerosis reports·2006
Same author

Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial.

Mayo Clinic proceedings·2006
Same author

The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients.

Medical care·2006
Same author

Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy.

Circulation·2005

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • National Cholesterol Education Program guidelines identify LDL-C as a key therapeutic target.
  • Adult Treatment Panel III (ATP III) guidelines update risk assessment for coronary heart disease (CHD).
  • Increased patient eligibility for lipid-lowering therapy necessitates novel treatment options.

Purpose of the Study:

  • To review current lipid-modifying agents and cholesterol metabolism.
  • To introduce ezetimibe, a new class of cholesterol absorption inhibitor.
  • To discuss the role of ezetimibe in managing dyslipidemia.

Main Methods:

  • Review of cholesterol metabolic pathways.
  • Analysis of mechanisms of action for lipid-modifying agents.
  • Presentation of clinical data on ezetimibe efficacy and safety.

Main Results:

  • Ezetimibe demonstrated an 18% reduction in LDL-C in Phase 2 trials.
  • Ezetimibe exhibited a tolerability and short-term safety profile comparable to placebo.
  • Current statin therapy is effective but not suitable for all patients.

Conclusions:

  • Ezetimibe represents a novel therapeutic approach for dyslipidemia.
  • Selective cholesterol absorption inhibition offers a new strategy for LDL-C lowering.
  • Ezetimibe provides an alternative for patients intolerant or unresponsive to statins.

Related Experiment Videos